OPKO Health (NASDAQ:OPK) Hits New 1-Year Low - Should You Sell?

Key Points

• OPKO shares hit a new 52-week low — the stock traded as low as $1.0950 and last at $1.0650 on high volume, signaling fresh near‑term selling pressure.
• Q1 results and guidance disappointed — Q1 revenue of $124.2M (down ~17% YoY) missed estimates and Q2 guidance of $127M–$132M came in below Street expectations, though GAAP EPS matched consensus.
• Pipeline progress provides long‑term potential but analysts remain cautious — ModeX is advancing five clinical programs and MDX2301 completed its first‑dose cohort, yet the consensus rating is "Hold" with an average price target of $1.55 and several firms on "sell" or "market perform."

Shares of OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) reached a new 52-week low during trading on Wednesday . The stock traded as low as $1.0950 and last traded at $1.0650, with a volume of 999750 shares traded. The stock had previously closed at $1.21.

More OPKO Health News

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: ModeX pipeline momentum — OPKO says ModeX is advancing five clinical programs, which supports longer‑term growth potential in its biologics platform. Opko outlines Q2 2026 revenue of $127M-$132M as ModeX advances 5 clinical programs
• Positive Sentiment: MDX2301 Phase 1 progress — the company initiated and completed the first‑dose cohort of MDX2301 (tetravalent bispecific antibody targeting COVID variants), a clinical milestone that de‑risks that program’s early development. OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
• Neutral Sentiment: Q1 EPS in line — GAAP loss per share of ($0.07) matched consensus, which reduces immediate earnings surprise risk. OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst stance unchanged — Barrington Research reaffirmed a "market perform" rating, signaling no upgrade from the sell‑side after the print. Benzinga
• Negative Sentiment: Revenue miss and YoY decline — Q1 revenue of $124.2M missed consensus (~$130.5M) and was down ~17% year‑over‑year, highlighting near‑term top‑line pressure. OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: Guidance below Street — OPKO set Q2 revenue guidance of $127M–$132M (below the ~$135.7M consensus) and FY revenue guidance roughly in a range that brackets but leans under some Street estimates; that trimmed near‑term upside. Opko outlines Q2 2026 revenue of $127M-$132M as ModeX advances 5 clinical programs

Analysts Set New Price Targets

Several research firms have recently commented on OPK. Barrington Research reissued a "market perform" rating on shares of OPKO Health in a report on Wednesday. Weiss Ratings reissued a "sell (d-)" rating on shares of OPKO Health in a report on Tuesday, April 21st. Finally, Wall Street Zen downgraded shares of OPKO Health from a "hold" rating to a "sell" rating in a report on Saturday, March 7th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, OPKO Health has an average rating of "Hold" and a consensus price target of $1.55.

OPKO Health Price Performance

The firm's fifty day moving average price is $1.18 and its 200 day moving average price is $1.28. The company has a quick ratio of 3.52, a current ratio of 3.97 and a debt-to-equity ratio of 0.26. The stock has a market cap of $800.82 million, a PE ratio of -3.52 and a beta of 1.49.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07). The company had revenue of $124.20 million for the quarter, compared to the consensus estimate of $130.51 million. OPKO Health had a negative net margin of 37.19% and a negative return on equity of 17.42%. OPKO Health's revenue was down 17.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.10) earnings per share. As a group, equities analysts expect that OPKO Health, Inc. will post -0.27 EPS for the current fiscal year.

Institutional Investors Weigh In On OPKO Health

A number of hedge funds have recently bought and sold shares of OPK. Goldman Sachs Group Inc. raised its stake in OPKO Health by 150.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company's stock valued at $7,544,000 after purchasing an additional 3,600,378 shares in the last quarter. Millennium Management LLC raised its stake in OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company's stock valued at $10,602,000 after purchasing an additional 1,798,385 shares in the last quarter. AQR Capital Management LLC raised its stake in OPKO Health by 466.7% during the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company's stock valued at $2,671,000 after purchasing an additional 1,324,988 shares in the last quarter. OP Asset Management Ltd purchased a new stake in OPKO Health during the first quarter valued at $1,257,000. Finally, HRT Financial LP purchased a new stake in OPKO Health during the fourth quarter valued at $851,000. Hedge funds and other institutional investors own 64.63% of the company's stock.

About OPKO Health

OPKO Health, Inc NASDAQ: OPK is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.